A PYMNTS Company

EU: EC to clear Takeda/Shire US$62b deal

 |  November 11, 2018

According to a report from Reuters, Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its US$62 billion bid for London’s Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday, November 9.

Last month, Takeda offered to divest Shire’s pipeline compound SHP647, along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.

Takeda is looking to the acquisition to boost its late-stage pipeline. Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to Takeda’s three. The deal would also make it a global top 10 drugmaker.

Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.